Chronic DLL4 blockade induces vascular neoplasms
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Delta-like 4 (DLL4)-mediated Notch signalling has emerged as an attractive target for cancer therapy. However, the potential side effects of blocking this pathway remain uncertain. Here we show that chronic DLL4 blockade causes pathological activation of endothelial cells, disrupts normal organ homeostasis and induces vascular tumours, raising important safety concerns.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, a chronic blockade of Notch signaling leads to vascular tumors of the liver, skin, ovary, testes and colon in mice [140, 141].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [141]
Citations
Cites
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis
Noguera-Troise, I., Daly, C., Papadopoulos, N. J., Coetzee, S., Boland, P., Gale, N. W., Chieh Lin, H., Yancopoulos, G. D., & Thurston, G. (2006) · Nature · doi:10.1038/nature05355 · Cited by 1,032
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis
Ridgway, J., Zhang, G., Wu, Y., Stawicki, S., Liang, W.-C., Chanthery, Y., Kowalski, J., Watts, R. J., Callahan, C., Kasman, I., et al. (2006) · Nature · doi:10.1038/nature05313 · Cited by 986
Self-citationHsieh, S. H., Ying, N. W., Wu, M. H., Chiang, W. F., Hsu, C. L., Wong, T. Y., Jin, Y. T., Hong, T. M., & Chen, Y. L. (2008) · Oncogene · doi:10.1038/sj.onc.1211029 · Cited by 229
Schmidt, M., Paes, K., De Mazière, A., Smyczek, T., Yang, S., Gray, A., French, D., Kasman, I., Klumperman, J., Rice, D. S., et al. (2007) · Development · doi:10.1242/dev.002576 · Cited by 183
Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications
Li, J., & Harris, A. L. (2009) · Frontiers in bioscience · doi:10.2741/3438 · Cited by 141
Promoting angiogenesis to a fault
Hicklin, D. J. (2007) · Nature Biotechnology · doi:10.1038/nbt0307-300 · Cited by 13
Different roads to inactivation
Seton-Rogers, S. E. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2719 · Cited by 8
Flintoft, L. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2081 · Cited by 1
Cited by
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
“However, chronic DLL4 blockage in healthy animals results in vascular neoplasm”
BackgroundBasic and Therapeutic Aspects of Angiogenesis
Potente, M., Gerhardt, H., & Carmeliet, P. (2011) · Cell · doi:10.1016/j.cell.2011.08.039 · Cited by 2,771
“Conversely, blockade of DLL4 or Notch1 in the adult causes vascular tumors and hemorrhage (Liu et al., 2011; Yan et al., 2010).”
Molecular control of endothelial cell behaviour during blood vessel morphogenesis
Herbert, S. P., & Stainier, D. Y. R. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3176 · Cited by 1,042
“However, recent evidence suggesting that chronic DLL4 blockade induces vascular tumours may hamper this effor”
BackgroundTargeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways
Takebe, N., Harris, P. J., Warren, R. Q., & Ivy, S. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.196 · Cited by 992
“Reported complications of continuous antibody-mediated inhibition of Notch include the development of angiomas and neovascular tuft formation”
BackgroundNotch Signaling in Development, Tissue Homeostasis, and Disease
Siebel, C., & Lendahl, U. (2017) · Physiological Reviews · doi:10.1152/physrev.00005.2017 · Cited by 978
Notch signaling: simplicity in design, versatility in function
Andersson, E. R., Sandberg, R., & Lendahl, U. (2011) · Development · doi:10.1242/dev.063610 · Cited by 950
Targeting the tumour vasculature: insights from physiological angiogenesis
Chung, A. S., Lee, J., & Ferrara, N. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2868 · Cited by 752
“Therefore, the possibility of targeting the DLL4 pathway for cancer therapy has received considerable attention, although recent studies have uncovered some serious toxicities associated with chronic DLL4 blockade, including the development of vascular tumour”
BackgroundMesoporous silica nanoparticles in medicine—Recent advances
Mamaeva, V., Sahlgren, C., & Lindén, M. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.07.018 · Cited by 707
“Due to the requirement of Notch activity in all tissues, general Notch inhibition gives rise to severe side effects [61,62] and no Notch inhibitors are in clinical use to date.”
BackgroundNotch Signaling in the Tumor Microenvironment
Meurette, O., & Mehlen, P. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.009 · Cited by 678
Vascular heterogeneity and specialization in development and disease
Potente, M., & Mäkinen, T. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.36 · Cited by 653
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
Welti, J., Loges, S., Dimmeler, S., & Carmeliet, P. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70212 · Cited by 591
Therapeutic modulation of Notch signalling — are we there yet?
Andersson, E. R., & Lendahl, U. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4252 · Cited by 457
Targeting Notch to Target Cancer Stem Cells
Pannuti, A., Foreman, K., Rizzo, P., Osipo, C., Golde, T., Osborne, B., & Miele, L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2823 · Cited by 450
“However, their chronic use can cause vascular neoplasms (99).”
BackgroundTargeting Notch signaling pathway in cancer: Clinical development advances and challenges
Takebe, N., Nguyen, D., & Yang, S. X. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.09.005 · Cited by 413
“However, continuous dosing with anti-DLL4 mAb has resulted in new vessel formation and angiomas in humans (Dufraine et al., 2008; Yan et al., 2010).”
Tumor Vessel Normalization by Chloroquine Independent of Autophagy
Maes, H., Kuchnio, A., Peric, A., Moens, S., Nys, K., De Bock, K., Quaegebeur, A., Schoors, S., Georgiadou, M., Wouters, J., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.06.025 · Cited by 410
“, 2011), and its inhibition evokes vascular remodeling and hyperbranching (Dill et al., 2012; Liu et al., 2011; Yan et al., 2010), properties that could explain CQ’s vessel normalization effects if its activity relied on Notch1 activation.”
BackgroundCoordinating cell behaviour during blood vessel formation
Geudens, I., & Gerhardt, H. (2011) · Development · doi:10.1242/dev.062323 · Cited by 376
“Also, specific blockade of DLL4-mediated notch signalling in mice using a DLL4-specific antibody resulted in liver pathologies characterised by abnormal activation of ECs (Yan et al., 2010).”
BackgroundFrom Fly Wings to Targeted Cancer Therapies: A Centennial for Notch Signaling
Ntziachristos, P., Lim, J. S., Sage, J., & Aifantis, I. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.018 · Cited by 374
Notch Signaling and the Skeleton
Zanotti, S., & Canalis, E. (2016) · Endocrine Reviews · doi:10.1210/er.2016-1002 · Cited by 321
Targeting angiogenesis in oncology, ophthalmology and beyond
Cao, Y., Langer, R., & Ferrara, N. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00671-z · Cited by 315
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
“Moreover, a chronic blockade of Notch signaling leads to vascular tumors of the liver, skin, ovary, testes and colon in mice [140, 141].”
BackgroundThe Notch signaling pathway as a mediator of tumor survival
Capaccione, K. M., & Pine, S. R. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt127 · Cited by 296
“A recent study of anti-DLL-4 antibody treatment resulted in significant pathological changes in the livers of rats and the formation of vascular neoplasms (135), raising concerns for patients following this treatment regimen.”
BackgroundTargeting Notch in oncology: the path forward
Majumder, S., Crabtree, J. S., Golde, T. E., Minter, L. M., Osborne, B. A., & Miele, L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00091-3 · Cited by 270
Notch Signaling in the Vasculature
Gridley, T. (2010) · Current Topics in Developmental Biology · doi:10.1016/s0070-2153(10)92009-7 · Cited by 271
“A potentially much more serious problem was revealed in a recent study that demonstrated chronic DLL4 blockade caused pathological activation of endothelial cells, resulted in histopathological changes in several organs, and induced the formation of vascular neoplasms (Yan et al., 2010).”
BackgroundControlling escape from angiogenesis inhibitors
Sennino, B., & McDonald, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3366 · Cited by 264
The neurovascular link in health and disease: molecular mechanisms and therapeutic implications
Quaegebeur, A., Lange, C., & Carmeliet, P. (2011) · Neuron · doi:10.1016/j.neuron.2011.07.013 · Cited by 247
“Like Dll4 blockade, loss of CCM1 results in hyperproliferative vascular lesions by activating b-catenin driven gene transcription (Glading and Ginsberg, 2010; Yan et al., 2010).”
Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited
Plate, K. H., Scholz, A., & Dumont, D. J. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1066-5 · Cited by 251
“been arisen since it has been reported that in preclinical models, chronic Dll4 blockade abnormally activates endothelial cells and causes vascular neoplasms [152].”
BackgroundCancer stem cells in glioblastoma—molecular signaling and therapeutic targeting
Huang, Z., Cheng, L., Guryanova, O. A., Wu, Q., & Bao, S. (2010) · Protein & Cell · doi:10.1007/s13238-010-0078-y · Cited by 248
“, 2009) but concern has been raised as chronic DLL4 targeting can induce neoplasia as well (Yan et al., 2010).”
BackgroundThe Spectrum of Achalasia: Lessons From Studies of Pathophysiology and High-Resolution Manometry
Kahrilas, P. J., & Boeckxstaens, G. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.038 · Cited by 235
Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting?
Sosa Iglesias, V., Giuranno, L., Dubois, L. J., Theys, J., & Vooijs, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00267 · Cited by 229
“mAb CT16 (anti-EGFR and antiNOTCH 2/3) SA ✓ ↓ Tumor-initiating capacity upon reimplantation, tumor growth and reversal of EMT phenotype ✓ Cetuximab and erlotinib-resistant cell lines: not effective (131) RT ✓ ↓ RT-enriched CD133+, EGFR inh-enriched ALDH+ ✓ ↓ The RT-induced EMT (upregulated in CD133+ but not in ALDH+ c…”
BackgroundInfluentialMamaeva, V., Rosenholm, J. M., Bate-Eya, L. T., Bergman, L., Peuhu, E., Duchanoy, A., Fortelius, L. E., Landor, S., Toivola, D. M., Lindén, M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.105 · Cited by 220
Mechanistic Insights into Notch Receptor Signaling from Structural and Biochemical Studies
Kovall, R. A., & Blacklow, S. C. (2010) · Current Topics in Developmental Biology · doi:10.1016/s0070-2153(10)92002-4 · Cited by 214
Notch receptor–ligand binding and activation: Insights from molecular studies
Chillakuri, C. R., Sheppard, D., Lea, S. M., & Handford, P. A. (2012) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2012.01.009 · Cited by 213
Vessel abnormalization: another hallmark of cancer?
De Bock, K., Cauwenberghs, S., & Carmeliet, P. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.10.008 · Cited by 213
“However, chronic blockage of its ligand Dll4 in healthy animals resulted in a dose-dependent formation of vascular neoplasms characterized by irregularly shaped blood vessels [58 ].”
BackgroundZhao, Q., Eichten, A., Parveen, A., Adler, C., Huang, Y., Wang, W., Ding, Y., Adler, A., Nevins, T., Ni, M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2728 · Cited by 205
“suggest that the reported changes in heart tissue after prolonged Dll4 blockade (19, 31) already start on a molecular level 24-hour posttreatment.”
BackgroundLeon, G., MacDonagh, L., Finn, S. P., Cuffe, S., & Barr, M. P. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.12.001 · Cited by 198
Al-Abd, A. M., Alamoudi, A. J., Abdel-Naim, A. B., Neamatallah, T. A., & Ashour, O. M. (2017) · Journal of Advanced Research · doi:10.1016/j.jare.2017.06.006 · Cited by 198
“ent animal species (mice, rats and monkeys) [69].”
BackgroundPotential therapeutic implications of cancer stem cells in glioblastoma
Cheng, L., Bao, S., & Rich, J. N. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.04.035 · Cited by 193
“raised as chronic DLL4 targeting can induce neoplasia as well [94].”
Choi, Y., & Jung, K. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01114-w · Cited by 188
“Long-term DLL4 blockade can lead to the development of vascular neoplasms, while persistent activation of DLL4 has been associated with T-cell acute lymphoblastic leukemia 23,76,77 .”
BackgroundThe Notch ligand Jagged1 as a target for anti-tumor therapy
Li, D. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00254 · Cited by 187
“The fact that chronic blockade of DLL4 causes severe pathological changes in animal models (154) makes alternative targets such as JAG1 even more appealing.”
BackgroundNotch in the Intestine: Regulation of Homeostasis and Pathogenesis
Noah, T. K., & Shroyer, N. F. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183741 · Cited by 183
VEGF-VEGFR Signals in Health and Disease
Shibuya, M. (2014) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2013.113 · Cited by 177
“However, although Dll4 blockade using these antibodies suppressed tubular formation by endothelial cells, these endothelial cells survived http://dx.doi.org/10.4062/biomolther.2013.113 in tissues and gave rise to angiomas (Yan et al., 2010).”
BackgroundInfluentialNotch ligand Delta-like 4 blockade attenuates atherosclerosis and metabolic disorders
Fukuda, D., Aikawa, E., Swirski, F. K., Novobrantseva, T. I., Kotelianski, V., Gorgun, C. Z., Chudnovskiy, A., Yamazaki, H., Croce, K., Weissleder, R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116889109 · Cited by 167
“The same study also reported the formation of vascular neoplasm by Dll4 Ab administration (67).”
BackgroundBlockade of individual Notch ligands and receptors controls graft-versus-host disease
Tran, I. T., Sandy, A. R., Carulli, A. J., Ebens, C., Chung, J., Shan, G. T., Radojcic, V., Friedman, A., Gridley, T., Shelton, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65477 · Cited by 165
“It also decreases concerns about unwanted effects of chronic Notch inhibition that may promote malignancies or perturb normal homeostasis (67–69).”
Self-citationEGFL7: a unique angiogenic signaling factor in vascular development and disease
Nichol, D., & Stuhlmann, H. (2012) · Blood · doi:10.1182/blood-2011-10-322446 · Cited by 162
Notch Inhibition as a Promising New Approach to Cancer Therapy
Purow, B. W. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0899-4_23 · Cited by 169
The double-edged sword of Notch signaling in cancer
South, A. P., Cho, R. J., & Aster, J. C. (2012) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2012.01.017 · Cited by 157
A systems biology view of blood vessel growth and remodelling
Logsdon, E. A., Finley, S. D., Popel, A. S., & Gabhann, F. M. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12164 · Cited by 187
Kangsamaksin, T., Murtomäki, A., Kofler, N. M., Cuervo, H., Chaudhri, R. A., Tattersall, I., Rosenstiel, P. E., Shawber, C. J., & Kitajewski, J. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0650 · Cited by 161
“dll4 blockade has also been found to have potential adverse events due to the hypersprouting in normal tissue vasculature (7).”
Jabs, M., Rose, A. J., Lehmann, L. H., Taylor, J., Moll, I., Sijmonsma, T. P., Herberich, S. E., Sauer, S. W., Poschet, G., Federico, G., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.029733 · Cited by 152
Self-citationChiorean, E. G., LoRusso, P. M., Strother, R. M., Diamond, J. R., Younger, A., Messersmith, W. A., Adriaens, L., Liu, L., Kao, R., DiCioccio, A. T., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2797 · Cited by 153
“Headache 18 (34) 1 (2) Anorexia 14 (26) 0 Back pain 13 (25) 0 Diarrhea 13 (25) 0 Peripheral edema 13 (25) 0 Dyspnea 12 (23) 3 (6)”
Notch signaling in developmental and tumor angiogenesis
Kofler, N. M., Shawber, C. J., Kangsamaksin, T., Reed, H. O., Galatioto, J., & Kitajewski, J. (2011) · Genes & Cancer · doi:10.1177/1947601911423030 · Cited by 142
Complementary Genomic Screens Identify SERCA as a Therapeutic Target in NOTCH1 Mutated Cancer
Roti, G., Carlton, A. L., Ross, K. N., Markstein, M., Pajcini, K. V., Su, A. H., Perrimon, N., Pear, W. S., Kung, A. L., Blacklow, S. C., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.015 · Cited by 149
“Additional murine studies indicate that Notch signaling may have a tumor suppressive function in other cell lineages as well, including myeloid progenitors (Klinakis et al., 2011) and endothelial cells (Liu et al., 2011; Yan et al., 2010).”
The Notch Pathway in Breast Cancer Progression
Kontomanolis, E. N., Kalagasidou, S., Pouliliou, S., Anthoulaki, X., Georgiou, N., Papamanolis, V., & Fasoulakis, Z. N. (2018) · The Scientific World JOURNAL · doi:10.1155/2018/2415489 · Cited by 142
The Warburg Effect in Endothelial Cells and its Potential as an Anti-angiogenic Target in Cancer
Fitzgerald, G., Soro-Arnáiz, I., & Bock, K. D. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00100 · Cited by 145
Pandya, K., Meeke, K., Clementz, A. G., Rogowski, A., Roberts, J., Miele, L., Albain, K. S., & Osipo, C. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.321 · Cited by 140
“For example, it is known that Delta-like 4 on endothelial cells engages and activates the Notch-1 receptor on cancer epithelial cells to promote angiogenesis (Yan et al, 2010).”
BackgroundDill, M. T., Rothweiler, S., Djonov, V., Hlushchuk, R., Tornillo, L., Terracciano, L., Meili‐Butz, S., Radtke, F., Heim, M. H., & Semela, D. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.052 · Cited by 139
Notch restricts lymphatic vessel sprouting induced by vascular endothelial growth factor
Zheng, W., Tammela, T., Yamamoto, M., Anisimov, A., Holopainen, T., Kaijalainen, S., Karpanen, T., Lehti, K., Ylä-Herttuala, S., & Alitalo, K. (2011) · Blood · doi:10.1182/blood-2010-11-317800 · Cited by 132
“Similar endothelial hyperreactivity was observed in certain blood vascular beds of rats and cynomolgus monkeys that were exposed to Notch inhibitors for prolonged periods of time.(36)”
Dll4-Notch signaling as a therapeutic target in tumor angiogenesis
Kuhnert, F., Kirshner, J. R., & Thurston, G. (2011) · Vascular Cell · doi:10.1186/2045-824x-3-20 · Cited by 135
“Further, the effects on liver function were shown to be reversible following cessation of treatment [79].”
Tung, J. J., Tattersall, I. W., & Kitajewski, J. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006601 · Cited by 146
“Longterm blockade of Dll4 in several mammalian models was found to cause hemorrhage-prone liver hemangiomas (Li et al. 2010; Yan et al. 2010; Ryeom 2011), likely because of development of the same overproliferated, delicate vessels seen elsewhere.”
BackgroundWälchli, T., Mateos, J. M., Weinmann, O., Babic, D., Regli, L., Hoerstrup, S. P., Gerhardt, H., Schwab, M. E., & Vogel, J. (2014) · Nature Protocols · doi:10.1038/nprot.2015.002 · Cited by 145
Developmental and pathological angiogenesis in the central nervous system
Vallon, M., Chang, J., Zhang, H., & Kuo, C. J. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1625-0 · Cited by 124
Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice
Liu, Z., Turkoz, A., Jackson, E. N., Corbo, J. C., Engelbach, J. A., Garbow, J. R., Piwnica-Worms, D. R., & Kopan, R. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43114 · Cited by 119
“Consistent with our observation, Yan and colleagues recently showed that chronic injection of Dll4 antibodies into adult mice, rats, and monkeys induces vascular neoplasm only in rats (37).”
BackgroundNotch Signalling in Breast Development and Cancer
Edwards, A. R., & Brennan, K. R. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.692173 · Cited by 130
“Rarer necrotic lesions were also identified in the heart and lungs (Yan et al., 2010).”
BackgroundMamaeva, V., Niemi, R., Beck, M., Özliseli, E., Desai, D., Landor, S. K.-J., Grönroos, T. J., Kronqvist, P., Pettersen, I. K. N., McCormack, E., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.42 · Cited by 120
“25,26 Antibody-based targeting of Notch ligands is associated with induction of vascular tumors in mice 27 and a variety of side effects including headache, hypertension, fatigue, right, and left ventricular dysfunction in patients in clinical trials.”
Huang, C., Li, Z., Li, N., Li, Y., Chang, A., Zhao, T., Wang, X., Wang, H., Gao, S., Yang, S., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.09.039 · Cited by 121
High mitogenic stimulation arrests angiogenesis
Pontes-Quero, S., Fernández-Chacón, M., Luo, W., Lunella, F. F., Casquero-García, V., García-Gónzalez, I., Hermoso, A., Rocha, S. F., Bansal, M., & Benedito, R. (2019) · Nature Communications · doi:10.1038/s41467-019-09875-7 · Cited by 124
Notch Signaling in Solid Tumors
Koch, U., & Radtke, F. (2010) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(10)92013-9 · Cited by 122
Targeting the Notch Signaling Pathway in Chronic Inflammatory Diseases
CHRISTOPOULOS, P. F., Gjølberg, T. T., Krüger, S., Haraldsen, G., Andersen, J. T., & Sundlisæter, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.668207 · Cited by 117
“However, mAb-based DLL-blockade in mice, rats or monkeys induced histopathological changes in the liver that were associated with development of subcutaneous neoplasms with uncertain malignant potential, which alludes to the fundamental role of the Notch system in mammalian physiology (112).”
Backgroundde Oliveira, R. L., Hamm, A., & Mazzone, M. (2011) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.04.001 · Cited by 133
Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry
Kluk, M., Ashworth, T. D., Wang, H., Knoechel, B., Mason, E. F., Morgan, E. A., Dorfman, D. M., Pinkus, G., Weigert, O., Hornick, J. L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067306 · Cited by 111
“Indeed, inhibition of notch signaling in rodents with inhibitory antibodies directed against the Notch ligand DLL4 leads to tumors in several organs that may be of vascular origin [56], and conditional knockout of notch1 in endothelial cells causes the appearance of vascular proliferations in the liver [19,20], sugges…”
Notching on Cancer’s Door: Notch Signaling in Brain Tumors
Teodorczyk, M., & Schmidt, M. H. H. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2014.00341 · Cited by 116
“One study showed that the treatment with anti-Dll4 antibody led to pathological changes in rat livers and the formation of vascular neoplasms, resembling hemangioblastomas (176).”
BackgroundNotch Signaling Regulates Immune Responses in Atherosclerosis
Sega, F. V. D., Fortini, F., Aquila, G., Campo, G. C., Vaccarezza, M., & Rizzo, P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01130 · Cited by 107
“reported adverse effects in the liver (148).”
Cancer Stem Cells, Quo Vadis? The Notch Signaling Pathway in Tumor Initiation and Progression
Meisel, C. T., Porcheri, C., & Mitsiadis, T. A. (2020) · Cells · doi:10.3390/cells9081879 · Cited by 109
Notch: Architect, Landscaper, and Guardian of the Intestine
Vooijs, M., Liu, Z., & Kopan, R. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.003 · Cited by 100
Djokovic, D., Trindade, A., Gigante, J., Badenes, M., Silva, L., Liu, R., Li, X., Gong, M., Krasnoperov, V. G., Gill, P. S., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-641 · Cited by 108
“Furthermore, given the concerns related to potential toxicity caused by therapeutic blockade of Dll4 signaling [20], conditional Dll4 knockout mice were used to assess the impact of chronic endothelial specific Dll4 loss-of-function.”
BackgroundInfluentialDll4-Notch signaling in regulation of tumor angiogenesis
Liu, Z., Fan, F., Wang, A., Zheng, S., & Lu, Y. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1534-x · Cited by 107
“Indeed, an antibody to Dll4, OMP-21M18, was the first therapeutic entity that selectively targeted the Notch pathway to enter human clinical trials (Yan et al. 2010).”
BackgroundRelevance of Notch Signaling for Bone Metabolism and Regeneration
Ballhause, T. M., Jiang, S., Baranowsky, A., Brandt, S., Mertens, P. R., Frosch, K., Yorgan, T. A., & Keller, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031325 · Cited by 101
Notch Signaling Regulates Antigen Sensitivity of Naive CD4+ T Cells by Tuning Co-stimulation
Laky, K., Evans, S., Pérez‐Díez, A., & Fowlkes, B. J. (2015) · Immunity · doi:10.1016/j.immuni.2014.12.027 · Cited by 101
“Our results suggest that strategies targeting DLL4 on CD11c cells (Kontermann, 2012) would offer powerful remedies for autoimmune disease without the adverse effects of systemic blockade of DLL4 (Pellegrinet et al., 2011; Yan et al., 2010).”
Impact of Notch Signaling on Inflammatory Responses in Cardiovascular Disorders
Quillard, T., & Charreau, B. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14046863 · Cited by 87
“In this respect, it has been shown that chronic Dll4 blockade induces vascular neoplasms [137].”
BackgroundEndothelial Krüppel-like Factor 4 Regulates Angiogenesis and the Notch Signaling Pathway
Hale, A. T., Tian, H., Anih, E., Recio, F. O., Shatat, M. A., Johnson, T., Liao, X., Ramírez‐Bergeron, D. L., Proweller, A., Ishikawa, M., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.530956 · Cited by 89
“However, there have been reports that chronic DLL4 blockade may actually induce vascular neoplasms in some contexts (41) and speculation that DLL4 blockade may work best as an anti-tumor agent when used in combination with anti-VEGF therapy.”
BackgroundCarlier, A., Geris, L., Bentley, K., Carmeliet, G., Carmeliet, P., & Oosterwyck, H. V. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002724 · Cited by 98
“It does not address EC quiescence and the fact that Notch activity in quiescent ECs will be associated with reduced VEGFR-2 receptor levels [25–27].”
BackgroundInfluentialAdam, M. G., Berger, C., Feldner, A., Yang, W.-J., Wüstehube-Lausch, J., Herberich, S. E., Pinder, M., Gesierich, S., Hammes, H.-P., Augustin, H. G., et al. (2013) · Circulation Research · doi:10.1161/circresaha.113.301686 · Cited by 84
“Such continuous Notch signaling is necessary to prevent the conversion into the tip cell phenotype,(9) to allow further vessel remodeling,(18) and even to prevent angiogenesis in mature vessels.(12,13)”
BackgroundTherapeutic Targeting of Notch Signaling: From Cancer to Inflammatory Disorders
Allen, F., & Maillard, I. P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.649205 · Cited by 91
Singh, A. K., Sharma, N., Ghosh, M., Park, Y. H., & Jeong, D. K. (2017) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2015.1129310 · Cited by 85
“However, the utility of Notch1 antibody-based targeting in isolation is questionable because of the redundancy of Notch receptor, ligands and questionable patient safety profile (Yan et al., 2010).”
BackgroundNotch in skeletal physiology and disease
CANALIS, E. M. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4694-3 · Cited by 89
Notch Signaling and Breast Cancer
Reedijk, M. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0899-4_18 · Cited by 90
Wälchli, T., Bisschop, J., Miettinen, A., Ulmann‐Schuler, A., Hintermüller, C., Meyer, E. P., Krucker, T., Waelchli, R., Monnier, P. P., Carmeliet, P., et al. (2021) · Nature Protocols · doi:10.1038/s41596-021-00587-1 · Cited by 83
Fibroblastic niches prime T cell alloimmunity through Delta-like Notch ligands
Chung, J., Ebens, C. L., Perkey, E., Radojčić, V., Koch, U., Scarpellino, L., Tong, A., Allen, F., Wood, S. C., Feng, J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89535 · Cited by 86
Self-citationMühleder, S., Fernández-Chacón, M., García-Gónzalez, I., & Benedito, R. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03664-y · Cited by 89
Notch: a key regulator of tumor angiogenesis and metastasis.
Garcia, A. J., & Kandel, J. J. (2012) · PubMed · doi:10.14670/hh-27.151 · Cited by 89
“Chronic Dll4 blockade led to thymic atrophy and ulcerating subcutaneous tumors in mouse models (Yan et al., 2010).”
BackgroundNotch signalling beyond liver development: Emerging concepts in liver repair and oncogenesis
Morell, C. M., Fiorotto, R., Fabris, L., & Strazzabosco, M. (2013) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2013.05.008 · Cited by 81
Schulz, G. B., Wieland, E., Wüstehube‐Lausch, J., Boulday, G., Moll, I., Tournier‐Lasserve, E., & Fischer, A. (2015) · Stroke · doi:10.1161/strokeaha.114.007512 · Cited by 82
Vascular targeting of adipose tissue as an anti-obesity approach
Daquinag, A. C., Zhang, Y., & Kolonin, M. G. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.01.004 · Cited by 78
Notch signaling: its roles and therapeutic potential in hematological malignancies
Gu, Y., Masiero, M., & Banham, A. H. (2016) · Oncotarget · doi:10.18632/oncotarget.7772 · Cited by 78
“These problems ranged from liver pathology to formation of vascular neoplasms due to abnormal endothelial cell activation, as normal Dll4 signaling is required to maintain these cells in a quiescent state [148].”
BackgroundBrennan, F. R., Cavagnaro, J., McKeever, K., Ryan, P. C., Schutten, M. M., Vahle, J., Weinbauer, G. F., Marrer-Berger, E., & Black, L. E. (2018) · mAbs · doi:10.1080/19420862.2017.1389364 · Cited by 70
“In CD40 or CD40L KO mice, there is little immunoglobulin (Ig) class switching or germinal center formation, and immune responses are severely inhibited,52,53 whilst human CD40L deficiency results in an inability to undergo Ig class switching and is associated with hyper-IgM syndrome.53 CD40L inhibition has also shown…”
BackgroundInfluentialCombining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience
Moreno, V., Basu, B., Molife, L. R., & Kaye, S. B. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1275 · Cited by 71
“However, recent studies showed that chronic DLL4 blockade can produce more vascular tumors in vivo, thus raising concerns over its clinical applicability (40).”
BackgroundRegulation of Blood and Lymphatic Vessels by Immune Cells in Tumors and Metastasis
Mazzone, M., & Bergers, G. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114721 · Cited by 74
“Although some tumors grew slowly due to inefficient blood supply as the result of this non-productive angiogenesis, the approach was soon abandoned because Delta-like 4 blockade could lead to the formation of vascular neoplasms (15), and Notch-1 haplodeficiency was associated with the formation of vascular tumors and…”
BackgroundInorganic nanoparticle-based advanced cancer therapies: Promising combination strategies
Amaldoss, M. J. N., Yang, J., Koshy, P., Unnikrishnan, A., & Sorrell, C. C. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103386 · Cited by 83
The Alarmin IL-33 Is a Notch Target in Quiescent Endothelial Cells
Sundlisæter, E., Edelmann, R. J., Fosse, J. H., Sponheim, J., Küchler, A. M., Weiss, M., Udalova, I. A., Midwood, K. S., Kasprzycka, M., & Haraldsen, G. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.06.003 · Cited by 82
“Likewise, chronic Dll4 blockade results in pathological activation of endothelial cells, with induction of vascular tumors in rat skin and perhaps also in heart and lung.(38) Thus, although blocking Dll4-Notch signaling to induce the formation of nonfunctional and nonperfused vessels has been suggested as a promising…”
BackgroundMolecular Pathways: Context-Dependent Approaches to Notch Targeting as Cancer Therapy
Egloff, A. M., & Grandis, J. R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2258 · Cited by 69
Metadata
- Authors
- Yan, M., Callahan, C. A., Beyer, J. C., Allamneni, K. P., Zhang, G., Ridgway, J. B., Niessen, K., & Plowman, G. D.
- Affiliations
- Genentech (US)
- Venue
- Nature
- Published
- 2010-02
- Volume
- 463
- Issue
- 7282
- Pages
- E6-E7
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2030370645
- Cited by
- 280
- References
- 8
- Citations by year
- 2026: 3 · 2024: 3 · 2023: 12 · 2022: 5 · 2021: 17 · 2020: 9 · 2019: 10 · 2018: 17 · 2017: 17 · 2016: 11 · 2015: 27 · 2014: 26 · 2013: 36 · 2012: 30
- FWCI
- 16.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Keywords
- DLL4, Notch signaling, vascular tumors, endothelial activation, drug safety, cancer treatment side effects, organ homeostasis, angiogenesis
- MeSH terms
- Animals, Antineoplastic Agents, Calcium-Binding Proteins, Humans, Macaca fascicularis, Membrane Proteins, Signal Transduction, Vascular Neoplasms, Endothelial Cells, Intracellular Signaling Peptides and Proteins, Adaptor Proteins, Signal Transducing, Mice, Rats, Receptors, Notch, Chemical and Drug Induced Liver Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.